Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends

Immune-checkpoint inhibitors (ICBs), in addition to targeting CTLA-4, PD-1, and PD-L1, novel targeting LAG-3 drugs have also been approved in clinical application. With the widespread use of the drug, we must deeply analyze the dilemma of the agents and seek a breakthrough in the treatment prospect....

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Qian, Hong, Zhenya, Zhang, Cong, Wang, Liangliang, Han, Zhiqiang, Ma, Ding
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460796/
https://www.ncbi.nlm.nih.gov/pubmed/37635168
http://dx.doi.org/10.1038/s41392-023-01522-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460796/
https://www.ncbi.nlm.nih.gov/pubmed/37635168
http://dx.doi.org/10.1038/s41392-023-01522-4

Ejemplares similares